Gilead Partners with Abingworth, securing $210M, for Trodelvy trials to develop a Trop-2-directed ADC

CAR-T Digest - August 2020

29 Feb 2024: Gilead Partners with Abingworth, securing $210M, for Trodelvy trials to develop a Trop-2-directed ADC

Gilead’s funding deal with VC shop Abingworth stands out as an unusual approach for a large drugmaker
- Abingworth to provide Gilead with $210M for Trodelvy ADC clinical trials, for NSCLC
- In exchange, Abingworth will receive a fixed payment upon regulatory approval in a specific indication, along with royalties from Trodelvy’s U.S. sales in NSCLC, while Gilead retains ownership of Trodelvy
The deal mitigates Gilead’s financial risks associated with advancing a drug crucial to its growing solid tumor business.
Despite the phase 3 EVOKE-01 trial in previously treated metastatic NSCLC failing its primary endpoint, Gilead maintains confidence in Trodelvy’s potential in NSCLC, citing a 3-month advantage in median overall survival (mOS) in a PD-1 progressor sub-group